Relay Therapeutics
Relay postpones its rare cancer drug approval plans due to IRA, losing ground to competitors
Anika Sharma
Relay Therapeutics is altering its strategic course, driven by the effects of the Inflation Reduction Act (IRA), leading the biotech ...
